Preview Mode Links will not work in preview mode

This Week in Cardiology

Jan 6, 2023

Damar Hamlin, obesity and semaglutide, Open Data and PCSK9 inhibitors, and TAVI vs SAVR trials are the topics John Mandrola, MD, discusses in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

I. Damar Hamlin

Five Thoughts on the Damar Hamlin Collapse

II. Semaglutide and Obesity in Adolescents

FDA Approves Wegovy (Semaglutide) for Obesity in Teens 12 and Up

Once-Weekly Semaglutide in Adolescents with Obesity

III. Open Data and PCSK9 inhibitors

Evolocumab Added to Statins Cuts CV Events in FOURIER Trial

Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction

Bendary Tweet

IV. Open Data and TAVI vs SAVR Trials

Risk of Bias in Randomized Clinical Trials Comparing Transcatheter and Surgical Aortic Valve Replacement

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact